Skip to content
buyWeak

Cormorant Asset Management, LP bought $9.1M of AMAM

owner at Ambrx Biopharma, Inc.. 1,307,311 shares at an average of $6.99, traded Oct 23, 2023, filed Oct 25, 2023.

Conviction score
35
Value
$9.1M
1,307,311 shares
Holdings after
11,231,000
+13% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    10% owner
    +12
  • Trade size
    $9.1M at market
    +25
  • Relative to holdings
    Holdings up 13%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (2 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000929638-23-002829, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 23, 2023POpen-market purchase
Common Stockindirect: See Footnotes
+1,307,311$6.99$9.1M11,231,000Oct 25, 2023

Related signals

Other insiders at Ambrx Biopharma, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
AMAMsell 210b5-1
Ambrx Biopharma, Inc.
Daniel J. O'Connor
President and CEO
$491k
50,012 shares
-13%
21Weak
AMAMsell 210b5-1
Ambrx Biopharma, Inc.
Sonja Nelson
Chief Financial Officer
$125k
12,778 shares
-9%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Cormorant Asset Management, LP bought $9.1M of AMAM | InsiderTell